Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Cerebrovascular disease and vascular risk factors are associated with Alzheimer's disease, but the evidence for their association with other neurodegenerative disorders is limited. Therefore, we compared the prevalence of cerebrovascular disease, vascular pathology and vascular risk factors in a wide range of neurodegenerative diseases and correlate them with dementia severity. Presence of cerebrovascular disease, vascular pathology and vascular risk factors was studied in 5715 cases of the National Alzheimer's Coordinating Centre database with a single neurodegenerative disease diagnosis (Alzheimer's disease, frontotemporal lobar degeneration due to tau, and TAR DNA-binding protein 43 immunoreactive deposits, α-synucleinopathies, hippocampal sclerosis and prion disease) based on a neuropathological examination with or without cerebrovascular disease, defined neuropathologically. In addition, 210 'unremarkable brain' cases without cognitive impairment, and 280 cases with pure cerebrovascular disease were included for comparison. Cases with cerebrovascular disease were older than those without cerebrovascular disease in all the groups except for those with hippocampal sclerosis. After controlling for age and gender as fixed effects and centre as a random effect, we observed that α-synucleinopathies, frontotemporal lobar degeneration due to tau and TAR DNA-binding protein 43, and prion disease showed a lower prevalence of coincident cerebrovascular disease than patients with Alzheimer's disease, and this was more significant in younger subjects. When cerebrovascular disease was also present, patients with Alzheimer's disease and patients with α-synucleinopathy showed relatively lower burdens of their respective lesions than those without cerebrovascular disease in the context of comparable severity of dementia at time of death. Concurrent cerebrovascular disease is a common neuropathological finding in aged subjects with dementia, is more common in Alzheimer's disease than in other neurodegenerative disorders, especially in younger subjects, and lowers the threshold for dementia due to Alzheimer's disease and α-synucleinopathies, which suggests that these disorders should be targeted by treatments for cerebrovascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, vascular pathologic signs have been found in 79.9% of AD patients.134”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [134]
In the citing paper
“Moreover, neuropathological studies indicate that early cerebrovascular disorder increases risk for dementia including AD (29) and is associated with AD and other neurodegenerative disorders independently of mixed dementias including vascular dementia (593).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [593]
In the citing paper
“In addition to the classic hallmark pathology, A 𝛃 plaques, hyperphosphorylated tau neurofibrillary tangles, and neuron loss, increasing evidence supports that early cerebrovascular dysfunction contributes to AD pathophysiology and cognitive impairment (29, 285, 418, 421, 429, 569, 571, 593, 682, 693).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [593]
In the citing paper
“However, vascular brain lesions lower the threshold of AD pathology required to induce dementia. 56,100-102”
From Vascular Cognitive Impairment (2017) · cites this paper as [101]
In the citing paper
“Recent clinical-pathological studies have highlighted the role of cerebrovascular disease, not only as a primary cause of cognitive impairment, but also as an adjuvant to the expression of dementia caused by other factors, including AD and other neurodegenerative pathologies (Gorelick et al., 2011; Schneider et al., 2007a; Toledo et al., 2013).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Toledo et al., 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Self-citation(2010) · Encyclopedia of Research Design · doi:10.4135/9781412961288.n40 · Cited by 1,995
(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“9% of AD patients.(134) Recently, an important study published by Yang et al.”
BackgroundReligious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
“pathologic studies are recruited at tertiary care dementia centers [3, 4].”
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement
Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., et al. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000034 · Cited by 852
Immune responses to stroke: mechanisms, modulation, and therapeutic potential.
Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135530 · Cited by 853
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
The overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739
“, lower neuritic Braak stages) [5], similar to earlier studies on respective associations with subcortical vascular pathology [6] and general CVD [1].”
BackgroundResultInfluentialVascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
“[5] Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al.”
Influentialvan der Flier, W. M., Skoog, I., Schneider, J. A., Pantoni, L., Mok, V., Chen, C. L. H., & Scheltens, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.3 · Cited by 594
Dichgans, M., & Leys, D. (2017) · Circulation Research · doi:10.1161/circresaha.116.308426 · Cited by 581
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationThe neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
Kalaria, R. N. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1571-z · Cited by 441
“Approximately, 20 % of these had lacunes and microinfarcts [164].”
BackgroundResultSantos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
White matter hyperintensities and imaging patterns of brain ageing in the general population
Habes, M., Erus, G., Toledo, J. B., Zhang, T., Bryan, N., Launer, L. J., Rosseel, Y., Janowitz, D., Doshi, J., Van der Auwera, S., et al. (2016) · Brain · doi:10.1093/brain/aww008 · Cited by 422
Self-citationDuncombe, J., Kitamura, A., Hase, Y., Ihara, M., Kalaria, R. N., & Horsburgh, K. (2017) · Clinical Science · doi:10.1042/cs20160727 · Cited by 401
Montero-Odasso, M. M., Sarquis-Adamson, Y., Speechley, M., Borrie, M. J., Hachinski, V. C., Wells, J., Riccio, P. M., Schapira, M., Sejdic, E., Camicioli, R. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0643 · Cited by 381
Neuropathology of Alzheimer's Disease
Trejo-Lopez, J. A., Yachnis, A. T., & Prokop, S. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 378
Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology
Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., & Bush, A. I. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0375-7 · Cited by 365
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Preventing dementia by preventing stroke: The Berlin Manifesto
Hachinski, V., Einhäupl, K., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zlokovic, B., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.001 · Cited by 313
Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study
Kawas, C. H., Kim, R. C., Sonnen, J. A., Bullain, S. S., Trieu, T., & Corrada, M. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001831 · Cited by 303
De Schepper, S., Ge, J. Z., Sierksma, A., Crowley, G., Ferreira, L. S. S., Garceau, D., Toomey, C. E., Sokolova, D., Rueda-Carrasco, J., Shin, S.-H., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01257-z · Cited by 295
“In support of this, vascular pathology is commonly observed in AD, afflicting approximately 80% of patients 66 .”
Attems, J., Toledo, J. B., Walker, L., Gelpi, E., Gentleman, S., Halliday, G., Hortobagyi, T., Jellinger, K., Kovacs, G. G., Lee, E. B., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02255-2 · Cited by 280
Self-citationThe Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
Stroke, Vascular Dementia, and Alzheimer’s Disease: Molecular Links
Vijayan, M., & Reddy, P. H. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160527 · Cited by 261
The Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
“These cerebrovascular pathologies are cortical infarcts, lacunes, hemorrhages, microbleeds, intracranial small vessel atherosclerosisarteriosclerosis, and blood brain barrier (BBB) dysfunction (Toledo et al., 2013).”
BackgroundThe Vascular Impairment of Cognition Classification Consensus Study
Skrobot, O. A., O'Brien, J., Black, S., Chen, C., DeCarli, C., Erkinjuntti, T., Ford, G. A., Kalaria, R. N., Pantoni, L., Pasquier, F., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.10.007 · Cited by 242
Prevention of dementia in an ageing world: Evidence and biological rationale
Grande, G., Qiu, C., & Fratiglioni, L. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101045 · Cited by 229
Yamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202
Kim, H., Leng, K., Park, J., Sorets, A. G., Kim, S., Shostak, A., Embalabala, R. J., Mlouk, K., Katdare, K. A., Rose, I. V. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34412-4 · Cited by 201
Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies
Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.036 · Cited by 198
Disentangling Heterogeneity in Alzheimer’s Disease and Related Dementias Using Data-Driven Methods
Habes, M., Grothe, M. J., Tunc, B., McMillan, C., Wolk, D. A., & Davatzikos, C. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.016 · Cited by 167
“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)
Nelson, P. T., Trojanowski, J. Q., Abner, E. L., Al-Janabi, O. M., Jicha, G. A., Schmitt, F. A., Smith, C. D., Fardo, D. W., Wang, W.-X., Kryscio, R. J., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw033 · Cited by 158
Self-citationCausal associations between modifiable risk factors and the Alzheimer's phenome
Andrews, S. J., Fulton‐Howard, B., O'Reilly, P., Marcora, E., Goate, A. M., & collaborators of the Alzheimer's Disease Genetics Consortium (2021) · Annals of Neurology · doi:10.1002/ana.25918 · Cited by 156
“Although VBI is not a classical neuropathological hallmark of AD, concurrent cerebrovascular injury is a common neuropathological finding in AD.(29) As such, VBI was included in the AD phenome to disentangle whether a particular risk factor may influence the clinical symptomatology of AD via vascular or amyloid/tau pa…”
BackgroundInfluentialLipid lowering and Alzheimer disease risk: A mendelian randomization study
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S., & Hingorani, A. D. (2020) · Annals of Neurology · doi:10.1002/ana.25642 · Cited by 157
Challenges of multimorbidity of the aging brain: a critical update
Jellinger, K. A., & Attems, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1288-x · Cited by 154
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Self-citationMukadam, N., Wolters, F. J., Walsh, S., Wallace, L., Brayne, C., Matthews, F. E., Sacuiu, S., Skoog, I., Seshadri, S., Beiser, A., et al. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00120-8 · Cited by 136
Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Implicating endothelial cell senescence to dysfunction in the ageing and diseased brain
Graves, S. I., & Baker, D. J. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13403 · Cited by 118
The blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Interplay between Brain Pericytes and Endothelial Cells in Dementia
Procter, T. V., Williams, A., & Montagne, A. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2021.07.003 · Cited by 106
“Gadolinium tracer leakage is seen in AD,42 APOE4 carriers at risk for AD,44 and cSVD.40 In addition, many of the MRI signs, such as white matter hyperintensities (WMHs), lacunes, microbleeds, and infarcts, are shared between the diseases, emphasizing their overlap.3,20,46,76 These lesions, which indicate tissue damage…”
BackgroundInfluentialWhite matter capillaries in vascular and neurodegenerative dementias
Hase, Y., Ding, R., Harrison, G., Hawthorne, E., King, A., Gettings, S., Platten, C., Stevenson, W., Craggs, L. J. L., & Kalaria, R. N. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0666-x · Cited by 101
“However, all neurodegenerative dementias bear some degree of vascular pathology ranging from 61% in frontotemporal dementias to 82% in AD [35].”
BackgroundRisk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals
Ighodaro, E. T., Abner, E. L., Fardo, D. W., Lin, A.-L., Katsumata, Y., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Neltner, J. H., Monsell, S. E., et al. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15621574 · Cited by 98
Self-citationExtracellular Vesicles of Alzheimer’s Disease Patients as a Biomarker for Disease Progression
Aharon, A., Spector, P., Ahmad, R. S., Horrany, N., Sabbach, A., Brenner, B., & Aharon-Peretz, J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02013-1 · Cited by 90
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
“Other neurodegenerative and non-degenerative disease pathologies commonly coexist in patients with dementia of the AD type (DAT) and community-dwelling subjects [2-5].”
Self-citationCerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease
Bryant, A. G., Hu, M., Carlyle, B. C., Arnold, S. E., Frosch, M. P., Das, S., Hyman, B. T., & Bennett, R. E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.575953 · Cited by 79
Self-citationStroke and Potentially Preventable Dementias Proclamation: Updated World Stroke Day Proclamation
Hachinski, V. (2015) · Stroke · doi:10.1161/strokeaha.115.011237 · Cited by 71
“• Understand that the presence of a vascular component doubles the chances that silent neurodegenerative pathology will lead to dementia.(10) • Manage the common risk factors for stroke, vascular cognitive impairment, dementia (tobacco use, high blood pressure, high cholesterol, physical inactivity, obesity, and diabe…”
BackgroundCSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
Self-citationInteraction between cerebrovascular disease and Alzheimer pathology
Saito, S., & Ihara, M. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000239 · Cited by 69
Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study
Klöppel, S., Peter, J., Ludl, A., Pilatus, A., Maier, S., Mader, I., Heimbach, B., Frings, L., Egger, K., Dukart, J., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150334 · Cited by 69
Thal, D. R., von Arnim, C. A. F., Griffin, W. S. T., Mrak, R. E., Walker, L., Attems, J., & Arzberger, T. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1360-6 · Cited by 67
Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports · doi:10.1038/srep20709 · Cited by 66
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
“Once a successful immunotherapy is developed, it will be important to establish if these people can benefit, as they account for a large percentage of the subjects with dementia [80].”
BackgroundZheng, B., Su, B., Ahmadi‐Abhari, S., Kapogiannis, D., Tzoulaki, I., Riboli, E., & Middleton, L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13349 · Cited by 34
Cykowski, M. D., Powell, S. Z., Schulz, P. E., Takei, H., Rivera, A. L., Jackson, R. E., Roman, G., Jicha, G. A., & Nelson, P. T. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0469-sa · Cited by 33
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Tham, R., & Schikowski, T. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200813 · Cited by 29
Kaskikallio, A., Karrasch, M., Koikkalainen, J., Lötjönen, J., Rinne, J. O., Tuokkola, T., Parkkola, R., & Grönholm-Nyman, P. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000506124 · Cited by 28
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease
Littau, J. L., Velilla, L., Hase, Y., Villalba‐Moreno, N. D., Hagel, C., Drexler, D., Osorio Restrepo, S., Villegas, A., Lopera, F., Vargas, S., et al. (2022) · Brain Pathology · doi:10.1111/bpa.13097 · Cited by 20
Sachdev, P. S. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000577 · Cited by 13
Breitner, J. C. S., Dodge, H. H., Khachaturian, Z. S., & Khachaturian, A. S. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12633 · Cited by 8
Daneshvar, D. H., Nowinski, C. J., Abdolmohammadi, B., Luster, C. B., Uretsky, M., Martin, B. M., Palmisano, J. N., Weuve, J., McClean, M. D., Cherry, J. D., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100418 · Cited by 17
Metadata
- Authors
- Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q.
- Affiliations
- University of Pennsylvania (US)
- University of Washington (US)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-10
- Volume
- 136
- Issue
- 9
- Pages
- 2697-2706
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3858112
- OpenAlex
- W2120070267
- Semantic Scholar
- b470677950c6c00bd6d262c34418a6589c2f44b1
- Cited by
- 849
- References
- 66
- Citations by year
- 2026: 48 · 2025: 94 · 2024: 79 · 2023: 67 · 2022: 94 · 2021: 79 · 2020: 77 · 2019: 77 · 2018: 41 · 2017: 46 · 2016: 51 · 2015: 51 · 2014: 33 · 2013: 11
- FWCI
- 34.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Brain (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01AG016976, P30AG010124, AG-10124, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- cerebrovascular disease, neurodegenerative diseases, Alzheimer's disease, vascular risk factors, vascular pathology, dementia severity, synucleinopathies, frontotemporal lobar degeneration, tau protein, TDP-43, prion disease, hippocampal sclerosis, autopsy neuropathology
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Autopsy, Cerebrovascular Disorders, Female, Health Surveys, Humans, Male, Middle Aged, Risk Factors, Sex Factors, United States, Dementia, Vascular, Prevalence, Neurodegenerative Diseases, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.